Penumbra

Yahoo Finance • 5 days ago

Why Boston Scientific Stock Plummeted Today

Key Points Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings were fine, and its future look... Full story

Yahoo Finance • 5 days ago

Boston Scientific shares slide on cautious 2026 revenue forecast

Feb 4 (Reuters) - Boston Scientific Corp forecast modest 2026 revenue growth and profit just ​below Wall Street expectations on Wednesday, ‌overshadowing a strong fourth-quarter performance and sending its shares down ‌more than 11% in pre... Full story

Yahoo Finance • 5 days ago

Boston Scientific announces results for fourth quarter and full year 2025

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 b... Full story

Yahoo Finance • 7 days ago

Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations

NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 7 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.Penumbra, Inc. (PRN... Full story

Yahoo Finance • 3 months ago

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a fu... Full story

Yahoo Finance • 3 months ago

Bullish Two Hundred Day Moving Average Cross - PEN

In trading on Monday, shares of Penumbra Inc (Symbol: PEN) crossed above their 200 day moving average of $175.34, changing hands as high as $179.68 per share. Penumbra Inc shares are currently trading up about 10.2% on the day. The chart... Full story

Yahoo Finance • 3 months ago

Penumbra raises 2025 revenue guidance to $1.375B–$1.38B as CAVT and embolization drive growth

Earnings Call Insights: Penumbra, Inc. (PEN) Q3 2025 MANAGEMENT VIEW * Adam Elsesser, Co-Founder, Chairman & CEO, opened by stating, "In the third quarter, we generated total revenue of $354.7 million, representing underlying year-over... Full story

Yahoo Finance • 3 months ago

Penumbra Enters Oversold Territory (PEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 4 months ago

Penumbra upgraded at Needham on revenue growth acceleration

[Wall Street in New York City] JaysonPhotography/iStock via Getty Images * Needham has upgraded Penumbra (NYSE:PEN [https://seekingalpha.com/symbol/PEN]) to buy from hold as it sees a boost in revenue growth in 2026. * The firm set a... Full story

Yahoo Finance • 4 months ago

Intel, FedEx downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Northrop Grumma... Full story

Yahoo Finance • 4 months ago

After-Hours Movers: Biotech And Medtech Stocks Jump On Volume And News

(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story

Yahoo Finance • 4 months ago

Deutsche Bank’s ‘Conviction list’ for Q4: KO, SCHW, LLY and more

[Journey of Distinction - Gradient Spheres Tapering Along Steps to a Singular Summit] J Studios/DigitalVision via Getty Images Deutsche Bank’s research team selected their top investment ideas to hold over the next 12 months, with new pic... Full story

Yahoo Finance • 5 months ago

Penumbra names Shruthi Narayan as president, effective September 1

* Penumbra (NYSE:PEN [https://seekingalpha.com/symbol/PEN]) announced on Wednesday the promotion of Shruthi Narayan to President, effective September 1, 2025. * Ms. Narayan was most recently president of Penumbra's interventional busi... Full story

Yahoo Finance • 6 months ago

Yuen, Penumbra CFO, sells $500k in shares

Penumbra Inc. (NASDAQ:PEN) Chief Financial Officer Maggie Yuen sold 2,000 shares of common stock on August 13, 2025, at a price of $250.0, totaling $500,000. The sale was executed under a Rule 10b5-1 trading plan. The medical devices compa... Full story

Yahoo Finance • 6 months ago

Arani Bose sells Penumbra shares worth $3m

Director Arani Bose sold 12,000 shares of Penumbra Inc (NASDAQ:PEN) common stock on August 13, 2025, for approximately $3,007,775. The transaction comes as Penumbra, with a market capitalization of $9.84 billion, maintains a "GREAT" financ... Full story

Yahoo Finance • 6 months ago

Penumbra Inc director Wilder sells $89k in stock

Director Thomas Wilder of Penumbra Inc (NYSE:PEN), a medical devices company with a market capitalization of $10.07 billion, sold 372 shares of common stock on August 12, 2025, at a price of $240.16, for a total value of $89,339. The stock... Full story

Yahoo Finance • 6 months ago

Should You Invest in Penumbra (PEN)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a... Full story

Yahoo Finance • 6 months ago

PEN Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of Penumbra Inc (Symbol: PEN) crossed above their 200 day moving average of $268.52, changing hands as high as $271.50 per share. Penumbra Inc shares are currently trading up about 4.3% on the day. The cha... Full story